176 related articles for article (PubMed ID: 21571382)
21. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer.
Yu X; Zhu Y; Wang J; Song X; Zhu L; Men X; Li X; Dai D; Xu W
Nucl Med Commun; 2017 Feb; 38(2):193-200. PubMed ID: 27977537
[TBL] [Abstract][Full Text] [Related]
25. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
[TBL] [Abstract][Full Text] [Related]
26. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
[TBL] [Abstract][Full Text] [Related]
27. How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.
Roengvoraphoj O; Eze C; Wijaya C; Dantes M; Taugner J; Tufman A; Huber RM; Bartenstein P; Belka C; Manapov F
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2103-2109. PubMed ID: 29876620
[TBL] [Abstract][Full Text] [Related]
28. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of standardised uptake value (SUV
Yilmaz Demirci N; Yilmaz Ü; Biner Uslu I; Dikmen A; Yılmaz A; Erdoğan Y
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26988938
[TBL] [Abstract][Full Text] [Related]
30. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
[TBL] [Abstract][Full Text] [Related]
31. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
32. Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study.
Yossi S; Krhili S; Muratet JP; Septans AL; Campion L; Denis F
Clin Nucl Med; 2015 Apr; 40(4):e215-21. PubMed ID: 25546211
[TBL] [Abstract][Full Text] [Related]
33. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy.
Xiang ZL; Erasmus J; Komaki R; Cox JD; Chang JY
Radiat Oncol; 2012 Aug; 7():144. PubMed ID: 22929048
[TBL] [Abstract][Full Text] [Related]
34. Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
Halvorsen TO; Herje M; Levin N; Bremnes RM; Brustugun OT; Fløtten Ø; Kaasa S; Sundstrøm S; Grønberg BH
Lung Cancer; 2016 Dec; 102():9-14. PubMed ID: 27987595
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
Zhang H; Wroblewski K; Pu Y
Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer.
Park SB; Choi JY; Moon SH; Yoo J; Kim H; Ahn YC; Ahn MJ; Park K; Kim BT
Cancer Imaging; 2014 Apr; 14(1):2. PubMed ID: 25609313
[TBL] [Abstract][Full Text] [Related]
37. [Positron emission tomography with 18F-FDG and cancer response to chemotherapy].
van Ruychevelt V; Garcia C; Meert AP; Berghmans T; Paesmans M; Flamen P; Sculier JP
Rev Mal Respir; 2011 May; 28(5):618-25. PubMed ID: 21645832
[TBL] [Abstract][Full Text] [Related]
38. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
39. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
